作者:
Remi,Samain [1]
;
Oscar,Maiques [1]
;
Joanne,Monger [1]
;
Hoyin,Lam [2]
;
Juliana,Candido [3]
;
Samantha,George [1]
;
Nicola,Ferrari [4]
;
Leonie,KohIhammer [1]
;
Sophia,Lunetto [5]
;
Adrian,Varela [6]
;
Jose L,Orgaz [1]
;
Felip,Vilardell [7]
;
Jorge Juan,Olsina [1]
;
Xavier,Matias-Guiu [1]
;
Debashis,Sarker [8]
;
Adrian,Biddle [9]
;
Frances R,Balkwill [10]
;
Jim,Eyles [9]
;
Robert W,Wilkinson [11]
;
Hemant M,Kocher [2]
;
Fernando,Calvo [7]
;
Claire M,Wells [1]
;
Victoria,Sanz-Moreno [4]
作者单位:
Centre for Tumour Microenvironment, Barts Cancer Institute, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, UK.
[1]
School of Cancer and Pharmaceutical Sciences, Kings College London, London SE1 1UL, UK.
[2]
GSK, R&D Portfolio, Strategy and Business Insights, GSK House, 980 Great West Road, Brentford, TW8 9GS, UK.
[3]
Oncology R&D, AstraZeneca, Cambridge CB21 6GH, UK.
[4]
Tumour Microenvironment Team, The Institute of Cancer Research, 237 Fulham Road, London SW3 6JB, UK.
[5]
Translational Science and Experimental Medicine, Early Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.
[6]
Centre for Cell Biology and Cutaneous Research, Blizard Institute, Queen Mary University of London, London E1 2AT, UK.
[7]
Instituto de Investigaciones Biomédicas Sols-Morreale CSIC-UAM, 28029 Madrid, Spain.
[8]
Department of Pathology, University Hospital Arnau de Vilanova, University of Lleida, Lleida, Spain.
[9]
Department of Surgery, University Hospital Arnau de Vilanova, University of Lleida, Lleida, Spain.
[10]
IRBLLEIDA, IDIBELL, University Hospita of Bellvitge, CIBERONC, Lleida, Spain.
[11]
Centre for Tumour Biology, Barts Cancer Institute, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, UK.
[12]
Barts and the London HPB Centre, The Royal London Hospital, Barts Health NHS Trust, London, UK.
[13]
Instituto de Biomedicina y Biotecnologia de Cantabria, c/ Albert Einstein 22, E39011 Santander, Spain.
[14]
DOI
10.1126/sciadv.adi0244
PMID
37851808
发布时间
2024-03-13